Contribution: Industrial Research Assistance Program – Contributions to Firms
3C Therapeutics Inc.
$84,000.00
Development of a Modular Linker Platform for Degrader-Antibody Conjugates (DAC)
EF 2025-26 · 2025-07-02
Résumé
This project combines antibody-drug conjugates (ADCs) with targeted protein degradation (TPD) via PROTACs (proteolysis targeting chimeras) to create a Degrader-Antibody Conjugate (DAC) - a novel dual-precision therapeutic molecule.
Ministère
Programme
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (lien de confiance élevée)
Bénéficiaire
Emplacement
North Vancouver|North Vancouver, British Columbia, Canada
Type de bénéficiaire
For-profit organization
Numéro d'entreprise
727026759
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Tel que publié
Agreement End Date
2026-03-31
Agreement Number
1032773
Agreement Start Date
2025-07-02
Agreement Title
Development of a Modular Linker Platform for Degrader-Antibody Conjugates (DAC)
Agreement Title (French)
Développement d’une plateforme modulaire de liaison pour les conjugués dégradeurs-anticorps (DAC)
Agreement Type
Contribution
Agreement Value
$84,000.00
Amendment Number
0
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
This project combines antibody-drug conjugates (ADCs) with targeted protein degradation (TPD) via PROTACs (proteolysis targeting chimeras) to create a Degrader-Antibody Conjugate (DAC) - a novel dual-precision therapeutic molecule.
Description (French)
Ce projet combine des conjugués anticorps-médicaments (ADC) avec la dégradation ciblée de protéines (TPD) via des PROTAC (chimères ciblant la protéolyse) afin de créer un conjugué dégradeur-anticorps (DAC), une nouvelle molécule thérapeutique à double précision.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
North Vancouver
Federal Riding (French)
North Vancouver
Federal Riding Number
59021
NAICS Code
541710
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
727026759
Recipient City
North Vancouver|North Vancouver
Recipient Country
CA
Recipient Legal Name
3C Therapeutics Inc.
Recipient Postal Code
V7K 1Y8
Recipient Province or Territory
BC
Recipient Type
F
Reference Number
172-2025-2026-Q2-1032773
